Hims & Hers Health, Inc. (NYSE:HIMS) Director Anja Manuel Acquires 4,000 Shares of Stock

Hims & Hers Health, Inc. (NYSE:HIMS) Director Anja Manuel bought 4,000 shares of the business’s stock in a transaction dated Tuesday, November 12th. The shares were bought at an average cost of $26.94 per share, for a total transaction of $107,760.00. Following the purchase, the director now directly owns 4,000 shares in the company, valued at approximately $107,760. This represents a ∞ increase in their position. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link.

Anja Manuel also recently made the following trade(s):

• On Thursday, November 14th, Anja Manuel acquired 1,000 shares of Hims & Hers Health stock. The shares were purchased at an average cost of $24.50 per share, for a total transaction of $24,500.00.

Hims & Hers Health Price Performance

NYSE HIMS traded down $0.92 during mid-day trading on Friday, reaching $19.93. The stock had a trading volume of 9,936,868 shares, compared to its average volume of 9,157,209. The stock has a market cap of $4.28 billion, a PE ratio of 47.38 and a beta of 1.06. Hims & Hers Health, Inc. has a 1 year low of $7.40 and a 1 year high of $30.44. The company has a fifty day moving average price of $19.64 and a 200 day moving average price of $18.78.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings data on Monday, November 4th. The company reported $0.32 EPS for the quarter, topping the consensus estimate of $0.06 by $0.26. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The company had revenue of $401.56 million during the quarter, compared to the consensus estimate of $382.20 million. During the same period last year, the company earned ($0.04) EPS. Hims & Hers Health’s revenue for the quarter was up 77.1% on a year-over-year basis. As a group, equities research analysts expect that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. Needham & Company LLC started coverage on Hims & Hers Health in a research note on Thursday, August 22nd. They issued a “buy” rating and a $24.00 target price for the company. Imperial Capital lowered Hims & Hers Health from an “outperform” rating to an “in-line” rating in a research report on Friday, August 9th. Piper Sandler reaffirmed a “neutral” rating and issued a $21.00 target price (up from $18.00) on shares of Hims & Hers Health in a research report on Tuesday, November 5th. Canaccord Genuity Group lifted their price target on shares of Hims & Hers Health from $24.00 to $28.00 and gave the company a “buy” rating in a research report on Tuesday, November 5th. Finally, Bank of America lowered shares of Hims & Hers Health from a “buy” rating to an “underperform” rating in a research note on Thursday. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and seven have given a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $21.21.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in HIMS. Nisa Investment Advisors LLC grew its position in Hims & Hers Health by 679.2% in the 2nd quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company’s stock worth $37,000 after purchasing an additional 1,603 shares during the period. Quest Partners LLC boosted its stake in shares of Hims & Hers Health by 5,944.1% in the 2nd quarter. Quest Partners LLC now owns 3,566 shares of the company’s stock worth $72,000 after buying an additional 3,507 shares during the last quarter. CWM LLC grew its holdings in shares of Hims & Hers Health by 21.4% in the third quarter. CWM LLC now owns 5,982 shares of the company’s stock worth $110,000 after acquiring an additional 1,054 shares during the period. Van ECK Associates Corp purchased a new stake in Hims & Hers Health during the second quarter valued at $111,000. Finally, Amalgamated Bank lifted its holdings in Hims & Hers Health by 55.9% in the second quarter. Amalgamated Bank now owns 6,566 shares of the company’s stock valued at $133,000 after acquiring an additional 2,354 shares during the period. 63.52% of the stock is owned by hedge funds and other institutional investors.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.